Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06516406
Recruiting Observational

Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

NCT06516406 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Observational
Started
2022-05-06
Last updated
2024-12-05

Condition(s) studied

MyelofibrosisPrimary MyelofibrosisSecondary Myelofibrosis

Study summary

The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice. * Availability of data on clinical history prior to initiation of Ruxolitinib therapy * Obtaining informed consent for data collection and processing Exclusion Criteria: * None

Primary outcome measure(s)

Trial sites (26)

FacilityCityRegionStatus
Azienda Ospedaliera Annunziata Cosenza Calabria Recruiting
Grande Ospedale Metropolitano "Bianchi Melacrino Morelli" Reggio Calabria Calabria Recruiting
Università degli Studi di Napoli Federico II U.O.C. di Ematologia e Trapianti di midollo Naples Campania Recruiting
IRCCS Policlinico Sant'Orsola Bologna Emilia-Romagna Recruiting
Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. Anna Ferrara Emilia-Romagna Recruiting
Azienda Ospedaliero-Universitaria di Parma Parma Emilia-Romagna Recruiting
AUSL di Piacenza - Palazzine Medicine Specialistiche Piacenza Emilia-Romagna Recruiting
Dipartimento Oncoematologico - AUSL della Romagna Ravenna Emilia-Romagna Recruiting
Ospedale Infermi di Rimini Rimini Emilia-Romagna Recruiting
A.O.U. Integrata di Udine Udine Friuli Venezia Giulia Recruiting
A.O.U. Policlinico Umberto I - Università degli Studi di Roma "La Sapienza" Rome Lazio Recruiting
Ospedale S. Eugenio Rome Lazio Recruiting
Ospedale Belcolle Viterbo Lazio Recruiting
IRCCS Azienda Ospedaliera Universitaria "San Martino" - IST Genoa Liguria Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Lombardy Recruiting
Ospedale San Gerardo Monza Lombardy Recruiting
Ospedale San Luigi Gonzaga - Regione Gonzole Turin Piedmont Recruiting
Department of Oncology, University of Torino Turin Piedmont Recruiting
Città della Salute e della Scienza Turin Piedmont Recruiting
A. O. Ordine Mauriziano di Torino Turin Piedmont Recruiting
Ospedale "A. Businco" - Dipartimento Scienze Mediche e Sanità Pubblica Università degli Studi di Cagliari Cagliari Sardinia Recruiting
A.O.U. "Policlinico-V. Emanuele"- P.O. Ferrarotto Catania Sicily Recruiting
A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore Pesaro The Marches Recruiting
Policlinico S.Maria alle Scotte Siena Tuscany Recruiting
AOU di Padova Padova Veneto Recruiting
A.O.U. Integrata Verona Verona Veneto Recruiting

More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy

Clinical and Immunological Outcomes of Living and Deceased Donor Transplantation Recruiting
Copeptin and Thirst: Possible Predictive Markers of Effectiveness of Bariatric Surgery? Recruiting
Comparison Between Two Hysteroscopic Biopsy Techniques in the Outpatient Setting for Sampling Hypotrophic or Atrophic Endometrium: 'Rail Biopsy' Versus 'Chip Biopsy' Recruiting
Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer Recruiting
Appropriateness of Colonoscopy Indication: an Evaluation of the Clinical and Economic Impact. Recruiting

Other trials for the same condition

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis Recruiting
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Active, not recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia Recruiting
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06516406 on ClinicalTrials.gov ↗ ← All trials in Italy